Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A concise synthetic pathway for trans-metanicotine analogues.

H Park1, J Jang, K S Sin

  • 1College of Pharmacy, Kangwon National University, Chunchon, Korea. haeilp@cc.kangwon.ac.kr

Archives of Pharmacal Research
|July 15, 2000
PubMed
Summary

A new 4-step synthesis for trans-metanicotine analogues was developed. These compounds are potential treatments for Alzheimer

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for CP violation in τ±→K(S)0π±ντ decays at Belle.

Physical review letters·2011
Same author

Search for three-jet resonances in pp collisions at square root(s)=7  TeV.

Physical review letters·2011
Same author

Relationship between body-mass index and serum folate concentrations in pregnant women.

European journal of clinical nutrition·2011
Same author

Measurement of the t-channel single top quark production cross section in pp collisions at √s=7  TeV.

Physical review letters·2011
Same author

Observation of transverse polarization asymmetries of charged pion pairs in e+e- annihilation near √s = 10.58 GeV.

Physical review letters·2011
Same author

Indications of suppression of excited Υ states in Pb-Pb collisions at √(s(NN))=2.76 TeV.

Physical review letters·2011

Area of Science:

  • Medicinal Chemistry
  • Organic Synthesis
  • Neuroscience

Background:

  • Trans-metanicotine is a selective ligand for the (alpha4beta2)-neuronal nicotinic acetylcholine receptor.
  • This receptor subtype is a therapeutic target for Alzheimer's disease, with trans-metanicotine currently in clinical trials.

Purpose of the Study:

  • To develop a convenient and efficient synthetic pathway for trans-metanicotine analogues.
  • To enable modifications at the alpha-position of the methylamino group for structure-activity relationship studies.

Main Methods:

  • The synthesis involved a four-step sequence starting with Zn-mediated allylation.
  • Subsequent steps included a Heck reaction, tosylation, and a substitution reaction with methylamine.

Main Results:

  • The pathway successfully yielded 5-pyridin-3-yl-pent-4-en-3-ol and methyl-(1-methyl-4-pyridin-3-yl-but-3-enyl)-amine (4) in good yields.
  • This method allows for the introduction of diverse functional groups at the alpha-position.

Conclusions:

  • A practical 4-step synthesis for trans-metanicotine analogues has been established.
  • This route facilitates the creation of novel compounds for potential Alzheimer's disease therapy.

Related Experiment Videos